학술논문
Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague-Dawley Rats But Aflibercept Affects Serum and Urine Metabolic Profiles.
Document Type
Academic Journal
Author
Forsgård RA; Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: richard.forsgard@helsinki.fi.; Marrachelli VG; Health research Institute INCLIVA, Metabolomics and Molecular Imaging Lab, Valencia, Spain; Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain. Electronic address: vannina.gonzalez@uv.es.; Lindén J; FCLAP, Department of Veterinary Biosciences, Faculty of Veterinary Medicine, University of Helsinki, Finland. Electronic address: jere.linden@helsinki.fi.; Frias R; Comparative Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: rafael.frias@ki.se.; Collado MC; Institute of Agrochemistry and Food Technology, National Research Council (IATA-CSIC), Valencia, Spain. Electronic address: mcolam@iata.csic.es.; Korpela R; Pharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: riitta.korpela@helsinki.fi.; Monleon D; Health research Institute INCLIVA, Metabolomics and Molecular Imaging Lab, Valencia, Spain. Electronic address: daniel.monleon@uv.es.; Spillmann T; Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland. Electronic address: thomas.spillmann@helsinki.fi.; Österlund P; Department of Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Oncology, Tampere University Hospital, Tampere, Finland. Electronic address: pia.osterlund@helsinki.fi.
Source
Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1936-5233 (Print) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1936-5233
Abstract
Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents. These biologics, however, possess a distinct toxicity profile, and they may also exacerbate the adverse effects of traditional chemotherapeutics. In this study, we aimed to characterize the gastrointestinal and metabolic changes after a 2-week treatment period with aflibercept, an antiangiogenic VEGFR decoy, and with erlotinib, a tyrosine-kinase inhibitor. Male rats were treated either with aflibercept or erlotinib for 2 weeks. During the 2-week treatment period, the animals in the aflibercept group received two subcutaneous doses of 25 mg/kg aflibercept. The erlotinib group got 10 mg/kg of erlotinib by oral gavage every other day. The control groups were treated similarly but received either saline injections or oral gavage of water. Intestinal toxicity was assessed by measuring intestinal permeability and by histological analyses of intestinal tissues. Metabolic changes were measured with 1 H nuclear magnetic resonance in serum and urine. Neither aflibercept nor erlotinib induced changes in intestinal permeability or intestinal tissue morphology. However, aflibercept treatment resulted in stunted body weight gain and altered choline, amino acid, and lipid metabolism. Two-week treatment with aflibercept or erlotinib alone does not induce observable changes in gastrointestinal morphology and function. However, observed aflibercept-treatment related metabolic changes suggest alterations in intestinal microbiota, nutrient intake, and adipose tissue function. The metabolic changes are also interesting in respect to the systemic effects of aflibercept and their possible associations with adverse events caused by aflibercept administration.
(Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
(Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)